Skip to main content
SpringerLink
Log in

Management of Primary Malignant Melanoma

  • Chapter
Melanoma

Part of the book series: Current Clinical Oncology ((CCO))

  • 126 Accesses

Abstract

Cutaneous malignant melanoma is widely recognized to be multifactorial in its etiology and development (1). There appears to be an increasingly recognized and documented set of causative environmental factors that may be superimposed upon underlying personal genetic substrate factors. Such combinations lead to a predisposition for developing malignant melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Schaffer JV, Bologna JL. The clinical spectrum of pigmented lesions. Clin Plast Surg 2000; 27: 391–408.

    PubMed  CAS  Google Scholar 

  2. Slade J, Marghoob AA, Salopek TG, Rigel DS, Kopf AW, Bart RS. Atypical mole syndrome: risk factor for cutaneous malignant melanoma and implications for management. J Am Acad Dermatol 1995; 32: 479–494.

    PubMed  CAS  Google Scholar 

  3. Graham S, Marshall J, Haughey B, et al. An inquiry into the epidemiology of melanoma. Am J Epidemiol 1985; 122: 606–619.

    PubMed  CAS  Google Scholar 

  4. Beral V, Evans S, Shaw H, et al. Cutaneous factors related to the risk of malignant melanoma. Br J Dermatol 1983; 109: 165–172.

    PubMed  CAS  Google Scholar 

  5. Dubin N, Moseson M, Pasternack BS. Epidemiology of malignant melanoma: pigmentary traits, ultraviolet radiation, and the identification of high-risk populations. Recent Results Cancer Res 1986; 102: 56–75.

    PubMed  CAS  Google Scholar 

  6. Graham S, Marshall J, Haughey B, et al. Op cit.

    Google Scholar 

  7. Elwood JM, Gallagher RP, Hill GB, et al. Pigmentation and skin reaction to sun as risk factors for cutaneous melanoma: Western Canada Melanoma Study. Br Med J 1984; 288: 99–102.

    Google Scholar 

  8. Green A, Bain C, McLennan R, et al. Risk factors for cutaneous melanoma in Queensland. Recent Results Cancer Res 1986; 102: 76–97.

    PubMed  CAS  Google Scholar 

  9. MacKie RM, Freudenberger T, Aitchison TC. Personal risk-factor chart for cutaneous melanoma. Lancet 1989; 2: 487–490.

    PubMed  CAS  Google Scholar 

  10. Holman CDJ, Armstron BK, Heenan PJ. Relationship of cutaneous malignant melanoma to individual sunlight-exposure habits. J Natl Cancer Inst 1986; 76: 403–414.

    PubMed  CAS  Google Scholar 

  11. Elwood JM, Williamson C, Stapleton PJ. Malignant melanoma in relation to moles, pigmentation, and exposure to fluorescent and other lighting sources. Br J Cancer 1986; 53: 65–74.

    PubMed  CAS  Google Scholar 

  12. Titus-Ernstoff L. An overview of the epidemiology of cutaneous melanoma. Clin Plast Surg 2000; 27: 305–316.

    PubMed  CAS  Google Scholar 

  13. Lancaster HO. Geographical aspects of melanoma. Lancet 1955; 2: 929.

    Google Scholar 

  14. Holman CDJ, Mulroney CD, Armstrong BK. Epidemiology of preinvasive and invasive malignant melanoma in Western Australia. Int J Cancer 1980; 25: 317–332.

    PubMed  CAS  Google Scholar 

  15. Mack TM, Floderus B. Malignant melanoma risk by nativity, place of residence at diagnosis, and age at migration. Cancer Causes Control 1991; 2: 401–411.

    PubMed  CAS  Google Scholar 

  16. Collins JJ, Devine N. Period and cohort factors in the incidence of malignant melanoma in the state of Connecticut. Environ Health Perspect 1984; 56: 255–259.

    PubMed  CAS  Google Scholar 

  17. Roush GC, Schymura MJ, Holford TR, et al. Time period compared to birth cohort in Connecticut incidence rates for twenty-five malignant neoplasms. J Natl Cancer Inst 1985; 74: 779–788.

    PubMed  CAS  Google Scholar 

  18. Thorn M, Bergstrom R, Adami HO, et al. Trends in the incidence of malignant melanoma in Sweden, by anatomic site, 1960–1984. Am J Epidemiol 1990; 132: 1066–1077.

    PubMed  CAS  Google Scholar 

  19. Venzon DJ, Mootgavkar SH. Cohort analysis of malignant melanoma in five countries. Am J Epidemiol 1984; 119: 62–70.

    PubMed  CAS  Google Scholar 

  20. Swerdlow AJ. International trends in cutaneous melanoma. Ann NY Acad Sci 1990; 609: 235–251.

    PubMed  CAS  Google Scholar 

  21. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997; 73: 198–203.

    PubMed  CAS  Google Scholar 

  22. Kraemer KH, Lee MM, Andrews AD, et al. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 1994; 130: 1018–1021.

    PubMed  CAS  Google Scholar 

  23. Swerdlow AJ, Weinstock MA. Do tanning lamps cause melanoma? An epidemiologic assessment. JAm Acad Dermatol 1998; 38: 89–98.

    CAS  Google Scholar 

  24. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (Psoralen) and ultraviolet A radiation (PUVA). NEngl JMed 1997; 336: 1041–1045.

    CAS  Google Scholar 

  25. Greene MH, Hoover RN, Fraumeni JF. Subsequent cancer in patients with chronic lymphocytic leukemia-a possible immunologic mechanism. J Natl Cancerinst 1978; 61: 337–340.

    CAS  Google Scholar 

  26. Greene MH, Young TL, Clark WH. Malignant melanomas in renal transplant recipients. Lancet 1981; 1: 1196–1199.

    PubMed  CAS  Google Scholar 

  27. Titus-Ernstoff L. op cit.

    Google Scholar 

  28. Clark WH Jr, Reimer RR, Greene M, et al. Origin of familial malignant melanomas from heritable melanocytic lesions: “the B-K mole syndrome.” Arch Dermatol 1978; 114: 732–738.

    PubMed  Google Scholar 

  29. Lynch HT, Frichot BC III, Lynch JF. Familial atypical multiple mole-melanoma syndrome. JMed Genet 1978; 15: 352–356.

    CAS  Google Scholar 

  30. Greene MH, Clark WH Jr, Tucker MA, et al. Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature. Lancet 1980; 2: 1024.

    PubMed  CAS  Google Scholar 

  31. Bondi EE, Clark WH Jr, Elder D, et al. Topical chemotherapy of dysplastic melanocytic nevi with 5% fluorouracil. Arch Dermatol 1981; 117: 89–92.

    PubMed  CAS  Google Scholar 

  32. Nollet DJ. “Clark’s nevus syndrome.” Am J Dermatopathol 1986; 8: 367.

    PubMed  CAS  Google Scholar 

  33. Consensus Development Panel on early melanoma. Diagnosis and treatment of early melanoma. JAMA 1992; 268: 1314–1319.

    Google Scholar 

  34. Kopf AW, Friedman RJ, Rigel DS. Atypical mole syndrome. JAm Acad Dermatol 1990; 22: 117–118.

    CAS  Google Scholar 

  35. Consensus Conference on Precursors to Malignant Melanoma. J Dermatol Surg Oncol 1985; 11: 537–542.

    Google Scholar 

  36. Consensus Development Panel on early melanoma. Op cit.

    Google Scholar 

  37. Lynch HT, Fusaro RM, Kimberling WJ, et al. Familial atypical multiple mole melanoma (FAMMM) syndrome: segregation analysis. JMed Genet 1983; 20: 342–344.

    CAS  Google Scholar 

  38. Bale SJ, Chakravanti A, Greene MH. Cutaneous malignant melanoma and familial dysplastic nevus: evidence for autosomal dominance and pleiotropy. Am J Hum Genet 1986; 38: 188–196.

    PubMed  CAS  Google Scholar 

  39. Bergman W, Palan A, Went LN. Clinical and genetic studies in six Dutch kindred with the dysplastic naevus syndrome. Ann Hum Genet 1986; 50: 249–258.

    PubMed  CAS  Google Scholar 

  40. Bale SJ, Dracopoli NC, Tucker MA, et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 1989; 320: 1367–1372.

    PubMed  CAS  Google Scholar 

  41. Goldstein AM, Dracopoli NC, Ho EC, et al. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet 1993; 52: 537–550.

    PubMed  CAS  Google Scholar 

  42. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13–22. Science 1992; 258: 1148–1152.

    PubMed  CAS  Google Scholar 

  43. Trent JM, Stanbridge EJ, McBride HL, et al. Tumorigenicity in human melanoma cell lines controlled by introduction human chromosome 6. Science 1990; 247: 568–571.

    Google Scholar 

  44. Koprowski H, Herlyn M, Balaban G, et al. Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somas Cell Mol Genet 1985; 11: 297–302.

    CAS  Google Scholar 

  45. Greene MH, Goldin RL, Clark WH Jr, et al. Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the RH locus. Proc Natl Acad Sci USA 1983; 80: 6071–6075.

    PubMed  CAS  Google Scholar 

  46. Goldstein AM, Dracopoli NC, Engelstein M, et al. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am JHum Genet 1994; 54: 489–496.

    PubMed  CAS  Google Scholar 

  47. Augustsson A, Steirner U, Rosdahl, I, et al. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol Suppl (Stockh) 1991; 71: 518–524.

    CAS  Google Scholar 

  48. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi: a central risk factor for cutaneous melanoma. JAMA 1997; 277: 1439–1444.

    PubMed  CAS  Google Scholar 

  49. Whiteman D, Green A. Melanoma and sunburn. Cancer Causes Control 1994; 5: 564–572.

    PubMed  CAS  Google Scholar 

  50. Beral V, Evans S, Shaw H, et al. Malignant melanoma and exposure to fluorescent lighting at work. Lancet 1982; 1: 290–293.

    Google Scholar 

  51. Weinstock MA. Do sunscreens increase or decrease melanoma risk: an epidemiologic evaluation. J Invest Dermatol Symp Proc 1999; 4: 97–100.

    CAS  Google Scholar 

  52. Vinceti M, Rothman KJ, Bergomi M, et al. Excess melanoma incidence in a cohort exposed to high levels of environmental selenium. Epidemiol Biomarkers Prevent 1998; 7: 853–856.

    CAS  Google Scholar 

  53. Bain C, Green A, Siskind V, et al. Diet and melanoma: an exploratory study. Ann Epidemiol 1993; 3: 235–238.

    PubMed  CAS  Google Scholar 

  54. Kirkpatrick CS, White E, Lee JAH. Case-control study of malignant melanoma in Washington state. II. Diet, alcohol, and obesity. Am J Epidemiol 1994; 139: 869–879.

    PubMed  CAS  Google Scholar 

  55. Beral V, Evans S, Shaw H, et al. Oral contraceptive use and malignant melanoma in Australia. Br J Cancer 1984; 50: 681–685.

    PubMed  CAS  Google Scholar 

  56. Osterlind A. Hormonal and reproductive factors in melanoma risk. Clin Dermatol 1992; 10: 75–78.

    PubMed  CAS  Google Scholar 

  57. Pfahlberg A, Hassan K, Wille L. Systematic review of case-control studies: oral contraceptives show no effect on melanoma risk. Public Health Rev 1997; 25: 309–315.

    PubMed  CAS  Google Scholar 

  58. Austin DF, Reynolds PJ, Snyder MA, et al. Malignant melanoma among employees of Lawrence Livermore National Laboratory. Lancet 1981; 2: 712–716.

    PubMed  CAS  Google Scholar 

  59. Antonelli NM, Dotters DJ, Katz VL, et al. Cancer in pregnancy: a review of the literature, Part I. Obstet Gynecol Sury 1996; 51: 125–134.

    CAS  Google Scholar 

  60. Langley RGB, Fitzpatrick TB, Sober AJ. Clinical characteristics. In: Balch CM, Houghton AN, Sober AJ, eds. Cutaneous Melanoma, 3rd ed. Quality Medical Publishing, St. Louis, 1998, pp. 82–101.

    Google Scholar 

  61. Langley RGB, Sober AJ. Causes for the delay in the diagnosis of melanoma. In: JJ Grob, RS Stern, RM Mackie, WA Weinstock, eds. Epidemiology, Causes and Prevention of Skin Diseases. Blackwell, Cambridge, UK, 1997, pp. 177–183.

    Google Scholar 

  62. Langley RGB, Barnhill RL, Mihm MC Jr, Fitzpatrick TB, Sober AJ. Neoplasms: cutaneous melanoma. In: Freedberg IM, Eisen AZ, Wolff K, et al., eds. Fitzpatrick’s Dermatology in General Medicine, 5th ed. McGraw-Hill, New York, 1999, pp. 1080–1116.

    Google Scholar 

  63. Sober AJ, Burstein JM. Computerized digital image analysis: an aid for melanoma diagnosis-preliminary investigations and brief review. J Dermatol 1994; 21: 885–890.

    PubMed  CAS  Google Scholar 

  64. Rajadhyaksha M, Grossman M, Esterowitz D, Webb RH, Anderson RR. In vivo confocal scanning laser microscopy of human skin: melar)r. provides strong contrast. J Invest Dermatol 1995; 104: 946–952.

    PubMed  CAS  Google Scholar 

  65. Albert LS, Fewkes J, Sober AJ. Metastatic lentigo maligna melanoma. J Dermatol Surg Oncol 1990; 16: 56–58.

    PubMed  CAS  Google Scholar 

  66. Pittelkow MR, Su WPD, Wick M, Sanchez N, Palestine R. Clinicopathologic study of lentigo malignant melanoma [abstract]. J Cutan Pathol 1986; 13: 75.

    Google Scholar 

  67. O’Donnel BF, Marsden JM, O’Donnel CA, et al. Does palpability of primary cutaneous melanoma predict dermal invasion? JAm Acad Dermatol 1995; 34: 923.

    Google Scholar 

  68. Su WPD. Malignant melanoma: basic approach to clinicopathologic correlation. Mayo Clin Proc 1997; 72: 267–272.

    PubMed  CAS  Google Scholar 

  69. Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987; 116: 303–310.

    PubMed  CAS  Google Scholar 

  70. Rhodes AR, Harrist Ti, Day CL Jr, et al. Dysplastic melanocytic nevi in histologic association with 234 cutaneous melanomas. JAm Acad Dermatol 1983; 9: 563–574.

    CAS  Google Scholar 

  71. Gruber SB, Barnhill RL, Stenn KS, et al. Nevomelanocytic proliferations in association with cutaneous malignant melanoma: a multivariate analysis. J Am Acad Dermatol 1989; 21: 773–780.

    PubMed  CAS  Google Scholar 

  72. MacKie RM. Malignant melanoma: clinical variants and prognostic indicators. Clin Exp Dermatol 2000; 25: 471–475.

    PubMed  CAS  Google Scholar 

  73. Clark WH Jr, Elder DE, Van Horn M. The biologic forms of malignant melanoma. Hum Pathol 1986; 17: 443–450.

    PubMed  Google Scholar 

  74. Manci EA, Balch CM, Murad TM, et al. Polypoid melanoma, a virulent variant of the nodular growth pattern. Am J Clin Pathol 1981; 75: 810–815.

    PubMed  CAS  Google Scholar 

  75. Stevens NG, Liff JM, Weiss NS. Plantar melanoma: is the incidence of melanoma of the sole of the foot really higher in blacks than in whites? Int J Cancer 1990; 45: 691–693.

    PubMed  CAS  Google Scholar 

  76. Saida T, Yoshida N, Ikegawa S, et al. Clinical guidelines for the early detection of plantar malignant melanoma. JAm Acad Dermatol 1990; 23: 37–40.

    CAS  Google Scholar 

  77. Ridgeway CA, Hieken TJ, Ronan SG, et al. Acral lentiginous melanoma. Arch Surg 1995; 130: 88–92.

    PubMed  CAS  Google Scholar 

  78. Blessing K, Kernohan NM, Park KGM. Subungual malignant melanoma: clinicopathological features of 100 cases. Histopathology 1991; 19: 425–429.

    PubMed  CAS  Google Scholar 

  79. Consensus Development Panel on Early Melanoma. Diagnosis and treatment of early melanoma. JAMA 1992; 268: 1314–1319.

    Google Scholar 

  80. Sober AJ, et al. AAD Guidelines of Care for Primary Cutaneous Melanoma (draft). Dermatol World, May 2000.

    Google Scholar 

  81. Ho VC, Sober AJ, Balch CM. Biopsy techniques. In: Balch CM, Houghton AN, Sober AJ, eds. Cutaneous Melanoma, 3rd ed. Quality Medical Publishing, St. Louis, 1998, pp. 135–140.

    Google Scholar 

  82. Zitelli JA, Moy RL, Abell E. The reliability of frozen sections in the evaluation of surgical margins for melanoma. JAm Acad Dermatol 1991; 24: 102–106.

    CAS  Google Scholar 

  83. Barnhill RL, Mihm MC Jr. Histopathology and precursor lesions. In: Balch CM, Houghton AN, Sober Ai, eds. Cutaneous Melanoma, 3rd ed. Quality Medical Publishing, St. Louis, 1998, pp. 103–133.

    Google Scholar 

  84. Cochran Ai, Wen D-R. S-100 protein as a marker for melanocytic and other tumours. Pathology 1985; 17: 340–345.

    PubMed  CAS  Google Scholar 

  85. Schmitt FC, Bacchi CE. S-100 protein: is it useful as a marker in diagnostic immunocytochemistry? Histopathology 1989; 15: 281–288.

    PubMed  CAS  Google Scholar 

  86. Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986; 123: 195–203.

    PubMed  CAS  Google Scholar 

  87. Wick MR, Swanson PE, Rocamora A. Recognition of malignant melanoma by monoclonal antibody HMB-45: an immunohistochemical study of 200 paraffin-embedded cutaneous tumors. J Cutan Pathol 1988; 15: 201–207.

    PubMed  CAS  Google Scholar 

  88. Smoller BR. Immunohistochemistry in the diagnosis of melanocytic neoplasms. Pathol State Art Rev 1994; 2: 371–383.

    CAS  Google Scholar 

  89. Daniel WP, Bradley RR. Amelanotic lentigo maligna. Arch Dermatol 1980; 116: 82–83.

    Google Scholar 

  90. Clark WH Jr. A classification of malignant melanoma in man correlated with histogenesis and biologic behavior. Adv Biol Skin 1967; 8: 621–647.

    Google Scholar 

  91. Breslow A. Thickness, cross sectional area and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902–908.

    PubMed  CAS  Google Scholar 

  92. Barnhill RL. Malignant melanoma: pathology and prognostic factors. Curr Opin Oncol 1993; 5: 364–376.

    PubMed  CAS  Google Scholar 

  93. Cosimi AB, Sober AJ, Mihm MC, Fitzpatrick TB. Conservative surgical management of superficially invasive cutaneous melanoma. Cancer 1984; 53: 1256–1259.

    PubMed  CAS  Google Scholar 

  94. Kelly JW, Sagebiel RW, Calderon W, Murillo L, Dakin RL, Blois MS. The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg 1984; 200: 759–763.

    PubMed  CAS  Google Scholar 

  95. O’Rourke MG, Altmann CR. Melanoma recurrence after excision. Is wide margin justified? Ann Surg 1993; 217: 2–5.

    PubMed  Google Scholar 

  96. Milton GW, Shaw HM, McCarthy WJ. Resection margins of melanoma. Aust NZ J Surg 1985; 55: 225–226.

    CAS  Google Scholar 

  97. Veronesi U, Cascinelli N, Adamus J, et al. Thin primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318: 1159–1162.

    PubMed  CAS  Google Scholar 

  98. Veronesi U, Cascinelli N. Narrow excision (1 cm margin): a safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126: 438–441.

    PubMed  CAS  Google Scholar 

  99. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2 cm surgical margins for intermediate-thickness melanomas (1 to 4 mm): results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218: 262–267.

    PubMed  CAS  Google Scholar 

  100. Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (4 mm) primary melanoma. Ann Surg Oncol 1998; 5: 322–328.

    PubMed  CAS  Google Scholar 

  101. Ross MI, Balch CM. Surgical treatment of primary melanoma. In: Balch CM, Houghton AN, Sober Ad, Soong SJ, eds. Cutaneous Melanoma, 3rd ed. Quality Medical Publishing, St. Louis, 1998; pp. 141–153.

    Google Scholar 

  102. Narayan D, Ariyan S. Surgical management of primary melanoma. Clin Plast Surg 2000; 27: 409–419.

    PubMed  CAS  Google Scholar 

  103. Urist MM. Surgical management of primary cutaneous melanoma. CA Cancer J Clin 1996; 46: 217–224.

    PubMed  CAS  Google Scholar 

  104. Schneebaum S, Briele HA, Walker MJ, et al. Cutaneous thick melanoma: prognosis and treatment. Arch Surg 1987; 122: 707–711.

    PubMed  CAS  Google Scholar 

  105. Spellman JE Jr, Driscoll D, Velez A, Karakousis C. Thick cutaneous melanoma of the trunk and extremities: an institutional review. Surg Oncol 1994; 3: 335–343.

    PubMed  Google Scholar 

  106. Hudson DA, Krige JE, Grobbelaar AO, Morgan B, Grover R. Melanoma of the face: the safety of narrow excision margins. Scand J Plast Reconstr Hand Surg 1998; 32: 97–104.

    CAS  Google Scholar 

  107. Cuono CB, Ariyan S. Versatility and safety of flap coverage for wide excision of cutaneous melanoma. Plast Reconstr Surg 1985; 76: 281–285.

    PubMed  CAS  Google Scholar 

  108. Balch CM, Soong SJ, Milton GW, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 1982; 196: 677–684.

    PubMed  CAS  Google Scholar 

  109. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma. III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1991; 193: 377–388.

    Google Scholar 

  110. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977; 297: 627–630.

    PubMed  CAS  Google Scholar 

  111. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986; 61: 697–705.

    PubMed  CAS  Google Scholar 

  112. Sim FH, Taylor WF, Ivins JC, Pritchard DJ, Soule EH. A prospective randomized study of the efficacy of routine elective lymphadenectomy in the management of malignant melanoma. Preliminary results. Cancer 1978; 41: 948–956.

    PubMed  CAS  Google Scholar 

  113. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996; 224: 255–263.

    PubMed  CAS  Google Scholar 

  114. Reintgen DS, Cox EB, McCarthy KS Jr, Vollmer RT, Seigler HF. Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg 1983; 198: 379–385.

    PubMed  CAS  Google Scholar 

  115. Balch CM, Soong S. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7: 87–97.

    PubMed  CAS  Google Scholar 

  116. Morton DL, Wen DR, Cochran AJ. Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy or “watch and wait.” Surg Oncol Clin North Am 1992; 1: 247.

    Google Scholar 

  117. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392–399.

    PubMed  CAS  Google Scholar 

  118. Reintgen DS, Cruse CW, Wells K, et al.. The orderly progression of melanoma nodal metastases. Ann Surg 1994; 220: 759–767.

    PubMed  CAS  Google Scholar 

  119. Thompson J, McCarthy WH, Bosch CM, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995; 5: 255–260.

    PubMed  CAS  Google Scholar 

  120. Ross MI, Reintgen DS, Balch CM. Selective lymphadenectomy: emerging role of lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 1993; 9: 219–223.

    PubMed  CAS  Google Scholar 

  121. Krag DN, Meijer SJ, Weaver DL, et al. Minimal-access surgery for staging of melanoma. Arch Surg 1995; 130: 654–658.

    PubMed  CAS  Google Scholar 

  122. Reintgen DS, Rapaport DP, Tanabe KK, Ross MI. Lymphatic mapping and sentinel lymphadenectomy. In: Balch CM, Houghton AN, Sober AJ, Soong SJ, eds. Cutaneous Melanoma, 3rd ed. Quality Medical Publishing, St. Louis, 1998; pp. 227–244.

    Google Scholar 

  123. Albertini JJ, Cruse CW, Rapaport D, et al. Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for melanoma patients. Ann Surg 1996; 223: 217–224.

    PubMed  CAS  Google Scholar 

  124. Wang X, Heller R, VanVoorhis N, et al. Detection of submicroscopic lymph node metastasis with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994; 220: 768–774.

    PubMed  CAS  Google Scholar 

  125. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16: 2253–2260.

    PubMed  CAS  Google Scholar 

  126. Slingluff CL Jr, Vollmer RT, Reintgen DS, Seigler HF. Lethal “thin” malignant melanoma. Identifying patients at risk. Ann Surg 1988; 208: 150–161.

    PubMed  Google Scholar 

  127. Balch CM, Buzaid AC. Finally a successful adjuvant therapy for high-risk melanoma [editorial]. J Clin Oncol 1996; 14: 1–3.

    PubMed  CAS  Google Scholar 

  128. Provost N, Marghoob AA, Kopf AW, DeDavid M, Wasti Q, Bart RS. Laboratory tests and imaging studies in patients with cutaneous malignant melanomas: a survey of experienced physicians. JAm Acad Dermatol 1997; 36: 711–720.

    CAS  Google Scholar 

  129. Olson JA Jr, Jaques DP, Coit DG, Hwu WJ. Staging work-up and post-treatment surveillance of patients with melanoma. Clin Plast Surg 2000; 27: 377–390.

    PubMed  Google Scholar 

  130. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O’Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995; 274: 1703–1705.

    PubMed  CAS  Google Scholar 

  131. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 1992; 8: 400–414.

    PubMed  CAS  Google Scholar 

  132. Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark’s and Breslow’s staging methods. Ann Surg 1978; 188: 732–742.

    PubMed  CAS  Google Scholar 

  133. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery 1979; 86: 343–351.

    PubMed  CAS  Google Scholar 

  134. Buttner P, Garbe C, Bertz J, et al. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark’s level for prognostic classification. Cancer 1995; 75: 2499–2506.

    PubMed  CAS  Google Scholar 

  135. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997; 15: 1039–1051.

    PubMed  CAS  Google Scholar 

  136. Schuchter L, Schultz DJ, Synnestvedt M, et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med 1996; 125: 369–375.

    PubMed  CAS  Google Scholar 

  137. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 976–983.

    PubMed  CAS  Google Scholar 

  138. Urist MM, Balch CM, Soong SJ, et al. Head and neck melanoma in 534 clinical Stage I patients. A prognostic factors analysis and results of surgical treatment. Ann Surg 1984; 200: 769–775.

    PubMed  CAS  Google Scholar 

  139. Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980; 45: 3012–3017.

    PubMed  CAS  Google Scholar 

  140. Buzaid AC, Tinoco LA, Jendiroba D, et al. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol 1995; 13: 2361–2368.

    PubMed  CAS  Google Scholar 

  141. Drepper H, Biess B, Hofherr B, et al. The prognosis of patients with stage III melanoma. Prospective long-term study of 297 patients of the Frachklinik Hornheide. Cancer 1993; 71: 1239–1246.

    PubMed  CAS  Google Scholar 

  142. Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg 1991; 214: 627–636.

    PubMed  CAS  Google Scholar 

  143. Karakousis CP, Hena MA, Emrich LJ, Driscoll DL. Axillary node dissection in malignant melanoma: results and complications. Surgery 1990; 108: 10–17.

    PubMed  CAS  Google Scholar 

  144. Koh HK, Sober AJ, Day CL Jr, et al. Prognosis of clinical stage I melanoma patients with positive elective regional node dissection. J Clin Oncol 1986; 4: 1238–1244.

    PubMed  CAS  Google Scholar 

  145. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991; 214: 491–499.

    PubMed  CAS  Google Scholar 

  146. Roses DF, Provet JA, Harris MN, Gumport SL, Dubin N. Prognosis of patients with pathologic stage II cutaneous malignant melanoma. Ann Surg 1985; 201: 103–107.

    PubMed  CAS  Google Scholar 

  147. Cascinelli N, Vaglini M, Nava M, et al. Prognosis of skin melanoma with regional node metastases (stage II). Surg Oncol 1984; 25: 240–247.

    CAS  Google Scholar 

  148. Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk; a randomised trial. WHO Melanoma Programme. Lancet 1998; 351: 793–796.

    PubMed  CAS  Google Scholar 

  149. Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998; 16: 1103–1111.

    PubMed  CAS  Google Scholar 

  150. Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983; 1: 126–134.

    PubMed  CAS  Google Scholar 

  151. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. JAm Coll Surg 1995; 181: 193–201.

    CAS  Google Scholar 

  152. Keilholz U, Conradt C, Legha SS, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16: 2921–2929.

    PubMed  CAS  Google Scholar 

  153. Deichmann M, Benner A, Bock M, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from non-progressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999; 17: 1891–1896.

    PubMed  CAS  Google Scholar 

  154. Agrawal S, Yao T-J, Coit DG. Surgery for melanoma metastatic to the gastrointestinal tract. Ann Surg Oncol 1999; 6: 336–344.

    PubMed  CAS  Google Scholar 

  155. Franzke A, Probst-Kepper M, Buer J, et al. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 1998; 78: 40–45.

    PubMed  CAS  Google Scholar 

  156. Sirott M, Bajorin D, Wong GY, et al. Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer 1993; 72: 3091–3098.

    PubMed  CAS  Google Scholar 

  157. Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 1997; 4: 252–258.

    PubMed  CAS  Google Scholar 

  158. Buzaid AC, Sandler AB, Mani S, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993; 11: 638–643.

    PubMed  CAS  Google Scholar 

  159. Khansur T, Sanders J, Das S. Evaluation of staging workup in malignant melanoma. Arch Surg 1989; 124: 847–849.

    PubMed  CAS  Google Scholar 

  160. Huang CL, Provost N, Marghoob AA, Kopf AW, Levin L, Bart RS. Laboratory tests and imaging studies in patients with cutaneous malignant melanoma. JAm Acad Dermatol 1998; 39: 451–463.

    CAS  Google Scholar 

  161. Coit DG. Role of surgery for metastatic malignant melanoma: a review. Semin Surg Oncol 1993; 9: 239–245.

    PubMed  CAS  Google Scholar 

  162. Au F, Maier W, Malmud L, Goldman LI, Clark WH Jr. Preoperative nuclear scans in patients with melanoma. Cancer 1984; 53: 2095–2097.

    PubMed  CAS  Google Scholar 

  163. Evans RA, Bland KI, McMurtrey MJ, Ballantyne AJ. Radionuclide scans not indicated for clinical stage I melanoma. Surg Gynecol Obstet 1980; 150: 532–534.

    PubMed  CAS  Google Scholar 

  164. Roth JA, Eilber FR, Bennett LR, Morton DL. Radionuclide photoscanning: usefulness in preoperative evaluation of melanoma patients. Arch Surg 1975; 110: 1211–1212.

    PubMed  CAS  Google Scholar 

  165. Zartman GM, Thomas MR, Robinson WA. Metastatic disease in patients with newly diagnosed malignant melanoma. J Surg Oncol 1987; 35: 163–164.

    PubMed  CAS  Google Scholar 

  166. Holder WD Jr, White RL, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998; 227: 764–769.

    PubMed  Google Scholar 

  167. Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998; 82: 1664–1671.

    PubMed  CAS  Google Scholar 

  168. Slingluff CL Jr, Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression. Implications for the concept of cure. Cancer 1992; 70: 1917–1927.

    PubMed  Google Scholar 

  169. Gadd MA, Coit DG. Recurrence patterns and outcome in 1019 patients undergoing axillary or inguinal lymphadenectomy for melanoma. Arch Surg 1992; 127: 1412–1416.

    PubMed  CAS  Google Scholar 

  170. Koh HK, Sober AJ, Fitzpatrick TB. Late recurrence (beyond ten years) of cutaneous malignant melanoma. Report of two cases and a review of the literature. JAMA 1984; 251: 1859 1862.

    Google Scholar 

  171. Crowley NJ, Seigler HF. Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg 1990; 212: 173–177.

    PubMed  CAS  Google Scholar 

  172. McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988; 166: 497–502.

    PubMed  CAS  Google Scholar 

  173. Warso MA, Das Gupta TK. Melanoma recurrence in a previously dissected lymph node basin. Arch Surg 1994; 129: 252–255.

    PubMed  CAS  Google Scholar 

  174. Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg 1993; 91: 94–98.

    PubMed  CAS  Google Scholar 

  175. Reintgen DS, Cox C, Slingluff CL, Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 1992; 28: 45–49.

    PubMed  CAS  Google Scholar 

  176. Mooney MM, Kulas M, McKinley B, Michalek AM, Kraybill WG. Impact on survival by method of recurrence detection in stage I and II cutaneous melanoma. Ann Surg Oncol 1998; 5: 54–63.

    PubMed  CAS  Google Scholar 

  177. Diagnosis and treatment of early melanoma. NIH Consensus Development Conference, January 27–29, 1992. NIH Consensus Statement 1992; 10: 1–25.

    Google Scholar 

  178. Houghton A, Coit DG, Bloomer W, et al. NCCN melanoma practice guidelines: National Comprehensive Cancer Network. Oncology 1998; 12: 153–177.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Philip L. Bailin MD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jon S. Meine MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christine Poblete-Lopez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center for Cancer Drug Discovery and Development, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH, USA

    Ernest C. Borden MD (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Humana Press Inc.,Totowa, NJ

About this chapter

Cite this chapter

Bailin, P.L., Meine, J.S., Poblete-Lopez, C. (2002). Management of Primary Malignant Melanoma. In: Borden, E.C. (eds) Melanoma. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-159-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-159-6_1

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9668-0

  • Online ISBN: 978-1-59259-159-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation